The clinical pipeline progress (RESTORE-FA and DT-818) is the primary catalyst, with 12-week data expected in Q1 2027. The DT-168 delay is a minor negative. Monitor for registrational plan update in Q4 2026. Cash runway into 2029 removes near-term financing risk.
Price Chart
Executive Summary
Design Therapeutics reported Q2 2026 financial results with a net loss of $20.2M ($0.32 per share), beating consensus of $0.34 loss per share. The key clinical updates include positive RESTORE-FA four-week data supporting trial modifications and initiation of DT-818 dosing in DM1, offset by a delay in DT-168 FECD Phase 2 data to 2027 due to supply issues. Cash position of $207.4M provides runway into 2029.
Key Financial Metrics
Key Facts
- Net loss of $20.2 million for Q2 2026, compared to $19.1 million in Q2 2025
- EPS of ($0.32) beat consensus estimate of ($0.34) by ~5.9%
- Cash and securities of $207.4 million as of June 30, 2026, down from $219.8 million at year-end 2025
- RESTORE-FA trial modified to focus on 1 mpk dose with 12-week cohort; primary endpoint changed to blood FXN protein percent change from baseline
- DT-818 Phase 1 MAD trial dosing initiated in myotonic dystrophy type 1 (DM1) patients
- DT-168 FECD Phase 2 data delayed to 2027 due to supply chain issue with blow-fill-seal eye droppers
- R&D expenses increased to $16.4 million from $15.7 million in Q2 2025
Financial Impact
Net loss of $20.2M, in line with expectations; cash burn rate ~$20M/quarter
Risk Factors
- Clinical trial execution risk for RESTORE-FA and DT-818
- DT-168 supply delay could impact FECD program timeline
- No revenue and continued operating losses
- Competitive landscape for Friedreich ataxia treatments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-329570 |
| Document: dsgn-20260803.htm | 0001193125-26-329570 |
| Document: 0001193125-26-329570-index-headers.html | 0001193125-26-329570 |
| Document: 0001193125-26-329570-index.html | 0001193125-26-329570 |
| Document: 0001193125-26-329570.txt | 0001193125-26-329570 |
| 8-K Data (Synthetic) | 0001193125-26-329570 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.34 (−18.97%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.34 (−18.97%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.34 (−3.36%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.34 (−34.52%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.34 (−17.48%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.34 (−7.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers